Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc (NQ: BEAM )

25.94 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 201
Open 25.94
Bid (Size) 26.29 (3)
Ask (Size) 27.76 (1)
Prev. Close 25.94
Today's Range 25.94 - 25.94
52wk Range 16.95 - 49.50
Shares Outstanding 79,199,501
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast
Via Benzinga
Beam Therapeutics Announces Transition of Chief Financial Officer
From Beam Therapeutics
Via GlobeNewswire

Performance

YTD
-5.36%
-5.36%
1 Month
+13.08%
+13.08%
3 Month
+7.63%
+7.63%
6 Month
+4.77%
+4.77%
1 Year
-17.78%
-17.78%

More News

Read More
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
Via InvestorPlace
3 Stocks With the Potential to 10X Your Money
Via InvestorPlace
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
Via InvestorPlace
Exposures Product Safety
Expert Ratings For Beam Therapeutics
Via Benzinga
Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts
Via Benzinga
Navigating 4 Analyst Ratings For Beam Therapeutics
Via Benzinga
3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.
Via InvestorPlace
Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
From Beam Therapeutics
Via GlobeNewswire
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
Via InvestorPlace
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
From Beam Therapeutics
Via GlobeNewswire
Popular Crypto Trader Shares 2024 Predictions For These Three Altcoins
Via Benzinga
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol
Via Benzinga
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
From Beam Therapeutics
Via GlobeNewswire
MarketBeat Week in Review – 3/4 – 3/8
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
Via MarketBeat
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.